Reneo Pharmaceuticals, Inc. financial data

Symbol
RPHM on Nasdaq
Industry
Pharmaceutical Preparations
Location
18575 Jamboree Road, Suite 275 S, Irvine, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.11K % -4.09%
Debt-to-equity 10.9 % +2.63%
Return On Equity -62.5 % -10.2%
Return On Assets -56.4 % -9.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.4M shares -1.1%
Common Stock, Shares, Outstanding 33.4M shares -1.12%
Entity Public Float 151M USD +291%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 33.4M shares +10.6%
Weighted Average Number of Shares Outstanding, Diluted 33.4M shares +10.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 36.8M USD -19.6%
General and Administrative Expense 25.1M USD +26.1%
Operating Income (Loss) -61.8M USD +5.71%
Net Income (Loss) Attributable to Parent -56.5M USD +7.69%
Earnings Per Share, Basic -1.68 USD/shares +28.2%
Earnings Per Share, Diluted -1.68 USD/shares +28.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36M USD +296%
Assets, Current 78M USD -46.7%
Property, Plant and Equipment, Net 81K USD -85.4%
Operating Lease, Right-of-Use Asset 493K USD -54.6%
Other Assets, Noncurrent 153K USD +93.7%
Assets 78.7M USD -46.8%
Accounts Payable, Current 64K USD -96.5%
Accrued Liabilities, Current 953K USD -91.8%
Liabilities, Current 1.35M USD -90.2%
Operating Lease, Liability, Noncurrent 492K USD -45.2%
Liabilities 1.85M USD -88.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -13K USD +58.1%
Retained Earnings (Accumulated Deficit) -232M USD -35.6%
Stockholders' Equity Attributable to Parent 76.9M USD -42%
Liabilities and Equity 78.7M USD -46.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21M USD -132%
Net Cash Provided by (Used in) Financing Activities 1.01M USD
Net Cash Provided by (Used in) Investing Activities 13.8M USD -25.7%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 33.4M shares -1.12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.26M USD -169%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36M USD +296%
Deferred Tax Assets, Valuation Allowance 49.9M USD +54.8%
Deferred Tax Assets, Gross 50M USD +53.9%
Operating Lease, Liability 823K USD -32.3%
Payments to Acquire Property, Plant, and Equipment 172K USD +291%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.5M USD +8.02%
Lessee, Operating Lease, Liability, to be Paid 851K USD -35.8%
Property, Plant and Equipment, Gross 254K USD -54.2%
Operating Lease, Liability, Current 331K USD +4.09%
Lessee, Operating Lease, Liability, to be Paid, Year Two 285K USD -25.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 371K USD -2.63%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28K USD -74.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 285K USD -25.2%
Deferred Tax Assets, Operating Loss Carryforwards 23.5M USD +43.4%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 11.4M USD +61.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 34K USD -88.1%
Operating Lease, Payments 96K USD -32.4%
Additional Paid in Capital 309M USD +1.73%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 16K USD -61%
Deferred Tax Assets, Net of Valuation Allowance 126K USD -55%
Share-based Payment Arrangement, Expense 4.82M USD +5.34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%